Mattoon, ILLINOIS1 Active Studies

Waldenstrom Macroglobulinemia Clinical Trials in Mattoon, ILLINOIS

Find 1 actively recruiting waldenstrom macroglobulinemia clinical trials in Mattoon, ILLINOIS. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
92
Enrolling

Recruiting Waldenstrom Macroglobulinemia Studies in Mattoon

About Waldenstrom Macroglobulinemia Clinical Trials in Mattoon

Waldenstrom macroglobulinemia is a rare type of non-Hodgkin lymphoma where cancer cells produce large amounts of an abnormal protein called macroglobulin. It progresses slowly and may not require immediate treatment. Options include targeted therapy, chemotherapy, and plasmapheresis.

There are currently 1 waldenstrom macroglobulinemia clinical trials recruiting participants in Mattoon, ILLINOIS. These studies are seeking a combined 92 participants. Research is being sponsored by National Cancer Institute (NCI). Clinical trial participation is free and participants receive study-related medical care at no cost.

Waldenstrom Macroglobulinemia Clinical Trials in Mattoon — FAQ

Are there waldenstrom macroglobulinemia clinical trials in Mattoon?

Yes, there are 1 waldenstrom macroglobulinemia clinical trials currently recruiting in Mattoon, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Mattoon?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Mattoon research site will contact you about next steps.

Are clinical trials in Mattoon free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Mattoon studies also compensate for your time and travel.

What waldenstrom macroglobulinemia treatments are being tested?

The 1 active trials in Mattoon are testing new therapies including novel drugs, biologics, and treatment approaches for waldenstrom macroglobulinemia.

Data updated March 2, 2026 from ClinicalTrials.gov